Biopharmaceutical News and Research

RSS

3SBio and Isotechnika enter strategic agreement for voclosporin in China

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products and Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, today announced the signing of a development and commercialization agreement for voclosporin.

24 Aug 2010

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the first patient has been treated in its clinical trial of STA-9090 in combination with docetaxel for the treatment of advanced solid tumor malignancies.

24 Aug 2010

Epilepsy Therapy Project, EF announce recipients of New Therapy Grants Program

The Epilepsy Therapy Project (ETP) and the Epilepsy Foundation (EF) today announced the latest grant recipients of its New Therapy Grants Program, a unique joint venture of the non-profit epilepsy organizations, to advance promising epilepsy research in clinical development. The grant awards, totaling approximately $200,000 in funding, will support an experimental gene therapy that directly targets epileptogenic brain tissue, as well as an electrode system that has the potential to improve the efficacy of surgical therapies for certain epilepsy syndromes.

24 Aug 2010

FDA OOPD awards Soligenix $1.2M for orBec Phase 3 study in acute gastrointestinal Graft-versus-Host-Disease

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that it has been awarded a three year $1.2 million clinical research grant by the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) pursuant to its Orphan Products Development (OPD) Program.

24 Aug 2010

Protalex initiates dosing in multicenter PRTX-100 Phase 1b clinical study in RA

Protalex, Inc., a clinical stage biopharmaceutical company engaged in developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, today announced the dosing of the first patient in a multicenter Phase 1b clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA). The study is being conducted in South Africa.

20 Aug 2010

JCI to pay $188 million for fraudulently obtaining confidential information of Hemispherx

Johannesburg Consolidated Investments Limited, a South African-based investment and finance company, was recently ordered to pay $188 million to Hemispherx Biopharma Inc. a biopharmaceutical company, for fraudulently obtaining confidential and proprietary information.

20 Aug 2010

Bioniche provides update on Urocidin clinical development program for non-muscle-invasive bladder cancer

Bioniche Life Sciences Inc., a research-based, technology driven Canadian biopharmaceutical company, today provided an update on the clinical development program for its proprietary product for non-muscle-invasive bladder cancer - Urocidin.

20 Aug 2010

FDA grants Acceleron's ACE-031 orphan designation for treatment of DMD

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.

20 Aug 2010

Trius Therapeutics second quarter 2010 revenue increases to $2.1 million

Trius Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections, announced today its financial results for the three months ended June 30, 2010.

20 Aug 2010

PAREXEL International launches temperature recording solution optimized for clinical trial supply process

PAREXEL International Corporation, a leading global biopharmaceutical services organization, today announced that it has introduced an integrated temperature recording solution for study drug transportation as part of its expanded Clinical Logistics Services.

From Parexel 19 Aug 2010

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has locked the database of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON™ (OX1).

18 Aug 2010

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Biogen Idec and Knopp Neurosciences today announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and potentially other indications.

18 Aug 2010

Endocyte files registration statement for public offering of common stock

Endocyte, Inc., a biopharmaceutical company developing targeted small-molecule drug conjugates, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.

18 Aug 2010

NeoStem second-quarter revenues increase 26% to $19.4 million

NeoStem, Inc. an international biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units, U.S. adult stem cells, China adult stem cells, and China pharmaceuticals is today providing results of its second quarter 2010.

16 Aug 2010

NIDA grants Selecta Biosciences $3M to develop nicotine vaccine for smoking cessation and relapse prevention

Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines and immunotherapies, today announced that it has been awarded a grant for $3 million from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health. The grant is aimed at advancing the development of an enhanced therapeutic nicotine vaccine for the treatment of smoking cessation and relapse prevention.

16 Aug 2010

China Biologic Products second-quarter revenues increase 23.3% to $40.9 million

China Biologic Products, Inc., one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. and its equity investment in Xi'an Huitian Blood Products Co., Ltd., today reported financial results for its second quarter ended June 30, 2010.

16 Aug 2010

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

Pharmaceutical research and biotechnology companies in New Jersey, California, New York and North Carolina are responsible for 192 of the 313 medicines in development today to treat mental illnesses, a new survey shows.

16 Aug 2010

US WorldMeds announces acquisition of Solstice Neurosciences for $35M

US WorldMeds, LLC, a Kentucky-based specialty pharmaceutical company that develops unique products to address unmet medical needs, today announced it has acquired Solstice Neurosciences, Inc. for $35 million. The acquisition expands US WorldMeds' operations, adds to the company's growing portfolio of products and enhances the company's ability to create and deliver high-quality specialty pharmaceutical products to its targeted global markets.

16 Aug 2010

Dyadic second-quarter 2010 total revenue decreases to $2.2 million

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the second quarter ended June 30, 2010.

13 Aug 2010

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2010.

13 Aug 2010

Biopharmaceutical News and Research

3SBio and Isotechnika enter strategic agreement for voclosporin in China

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Epilepsy Therapy Project, EF announce recipients of New Therapy Grants Program

FDA OOPD awards Soligenix $1.2M for orBec Phase 3 study in acute gastrointestinal Graft-versus-Host-Disease

Protalex initiates dosing in multicenter PRTX-100 Phase 1b clinical study in RA

JCI to pay $188 million for fraudulently obtaining confidential information of Hemispherx

Bioniche provides update on Urocidin clinical development program for non-muscle-invasive bladder cancer

FDA grants Acceleron's ACE-031 orphan designation for treatment of DMD

Trius Therapeutics second quarter 2010 revenue increases to $2.1 million

PAREXEL International launches temperature recording solution optimized for clinical trial supply process

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Endocyte files registration statement for public offering of common stock

NeoStem second-quarter revenues increase 26% to $19.4 million

NIDA grants Selecta Biosciences $3M to develop nicotine vaccine for smoking cessation and relapse prevention

China Biologic Products second-quarter revenues increase 23.3% to $40.9 million

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

US WorldMeds announces acquisition of Solstice Neurosciences for $35M

Dyadic second-quarter 2010 total revenue decreases to $2.2 million

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News